# Cytoship

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytoship

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Latest round: Angel (Apr 7, 2025)
- Investors on record: 4

## About

Based in Chengdu, China, and founded in 2024, Saiyun Biotechnology (Chengdu) Co., Ltd., trading as Cytoship, operates as a developer of targeted delivery technology and innovative drug therapies, focusing on tumor targeted therapy and cell gene therapy. The company has set up a research and development laboratory in Beijing. In January 2026, Cytoship raised a venture funding from FOF Capital.

Cytoship focuses on the development of delivery carrier technology and innovative drug therapies, and has developed a bionic delivery system. This delivery system delivers payloads such as functional biomacromolecules directly into specific cells. The company's products can be used in the fields of tumors, genetic diseases, skin, intestinal tract, etc.

The company generates revenue by developing and providing bionic delivery systems.

## Funding rounds

- Angel, Apr 7, 2025 — Casstar Capital
- Angel, Oct 28, 2024 — IDG Capital, Innoangel Fund, Zhongguancun Development Venture

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Angel
- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Angel
- Zhongguancun Development Venture (https://capitalatlas.ai/funds/zhongguancun-development-venture) — Angel
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel